(MedPage Today) -- The market for compounded GLP-1 drugs remained robust despite the end of semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) shortages, with many facilities adding ingredients like B vitamins and some operating...